254 related articles for article (PubMed ID: 18756533)
1. Clofarabine combinations as acute myeloid leukemia salvage therapy.
Faderl S; Ferrajoli A; Wierda W; Huang X; Verstovsek S; Ravandi F; Estrov Z; Borthakur G; Kwari M; Kantarjian HM
Cancer; 2008 Oct; 113(8):2090-6. PubMed ID: 18756533
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
[TBL] [Abstract][Full Text] [Related]
4. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Faderl S; Verstovsek S; Cortes J; Ravandi F; Beran M; Garcia-Manero G; Ferrajoli A; Estrov Z; O'Brien S; Koller C; Giles FJ; Wierda W; Kwari M; Kantarjian HM
Blood; 2006 Jul; 108(1):45-51. PubMed ID: 16403905
[TBL] [Abstract][Full Text] [Related]
6. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S; Ravandi F; Huang X; Garcia-Manero G; Ferrajoli A; Estrov Z; Borthakur G; Verstovsek S; Thomas DA; Kwari M; Kantarjian HM
Blood; 2008 Sep; 112(5):1638-45. PubMed ID: 18565853
[TBL] [Abstract][Full Text] [Related]
8. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
[TBL] [Abstract][Full Text] [Related]
9. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
[TBL] [Abstract][Full Text] [Related]
10. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Krauter J; Fiedler W; Schlenk RF; Paschka P; Thol F; Lübbert M; Wattad M; Verbeek M; Könecke C; Neuhaus B; Papkalla A; Kebenko M; Janning M; Döhner K; Gaidzik VI; Becker H; Greil C; Reimer P; Götze KS; Döhner H; Ganser A; Heuser M
Br J Haematol; 2018 Oct; 183(2):235-241. PubMed ID: 30378121
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Faderl S; Wetzler M; Rizzieri D; Schiller G; Jagasia M; Stuart R; Ganguly S; Avigan D; Craig M; Collins R; Maris M; Kovacsovics T; Goldberg S; Seiter K; Hari P; Greiner J; Vey N; Recher C; Ravandi F; Wang ES; Vasconcelles M; Huebner D; Kantarjian HM
J Clin Oncol; 2012 Jul; 30(20):2492-9. PubMed ID: 22585697
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
14. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
15. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Agura E; Cooper B; Holmes H; Vance E; Berryman RB; Maisel C; Li S; Saracino G; Tadic-Ovcina M; Fay J
Oncologist; 2011; 16(2):197-206. PubMed ID: 21273514
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia.
Martínez-Cuadrón D; Montesinos P; Oriol A; Salamero O; Vidriales B; Bergua J; Herrera P; Vives S; Sanz J; Carpio C; Rodríguez-Veiga R; Moscardó F; Sanz MA
Ann Hematol; 2014 Jan; 93(1):43-6. PubMed ID: 24081577
[TBL] [Abstract][Full Text] [Related]
19. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Horton TM; Perentesis JP; Gamis AS; Alonzo TA; Gerbing RB; Ballard J; Adlard K; Howard DS; Smith FO; Jenkins G; Kelder A; Schuurhuis GJ; Moscow JA
Pediatr Blood Cancer; 2014 Oct; 61(10):1754-60. PubMed ID: 24976003
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
